A Study of Navenibart in Participants With Hereditary Angioedema
Public ClinicalTrials.gov record NCT06842823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants With Hereditary Angioedema (HAE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Study identification
- NCT ID
- NCT06842823
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 157 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2025 (Actual)
- Primary completion
- Dec 2026 (Estimated)
- Completion
- Jun 2027 (Estimated)
- Last update posted
- Jun 30, 2026
2025 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 9 | Birmingham | Alabama | 35209 | — |
| Site 2 | Scottsdale | Arizona | 85251 | — |
| Site 3 | Little Rock | Arkansas | 72205 | — |
| Site 26 | San Diego | California | 92122 | — |
| Site 14 | San Diego | California | 92123, | — |
| Site 4 | Santa Monica | California | 90404 | — |
| Site 1 | Walnut Creek | California | 94598 | — |
| Site 8 | Centennial | Colorado | 80112 | — |
| Site 11 | Colorado Springs | Colorado | 80907 | — |
| Site 25 | Tampa | Florida | 33613 | — |
| Site 69 | Weston | Florida | 33331 | — |
| Site 6 | Wheaton | Maryland | 20902 | — |
| Site 67 | Boston | Massachusetts | 02114 | — |
| Site 13 | Detroit | Michigan | 48202 | — |
| Site 10 | St Louis | Missouri | 63141 | — |
| Site 7 | Cincinnati | Ohio | 45236 | — |
| Site 12 | Toledo | Ohio | 43617 | — |
| Site 15 | Hummelstown | Pennsylvania | 17036 | — |
| Site 86 | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06842823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06842823 live on ClinicalTrials.gov.